<DOC>
	<DOCNO>NCT01900496</DOCNO>
	<brief_summary>This research do study combination Brentuximab vedotin Rituximab treatment relapse Hodgkin 's Lymphoma ( HL ) .</brief_summary>
	<brief_title>Study Rituximab Brentuximab Vedotin Relapsed Classical Hodgkin Lymphoma</brief_title>
	<detailed_description>This research do study combination drug relapse Hodgkin 's Lymphoma ( HL ) may easier tolerate standard therapy involve autologous blood marrow transplant ( BMT , also call stem cell transplant ) .The study people HL never receive treatment relapse lymphoma , except radiation therapy . Usually , HL relapse first time , standard receive combination chemotherapy , include autologous blood marrow transplant ( BMT , also call stem cell transplant ) 40 % cure rate . BMT may cure HL , also may associate serious side effect risk . This research look combination drug relapse HL may side effect standard therapy involve BMT . The goal treat lymphoma effectively drug expect few side effect , avoid treatment like BMT .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age &gt; 16 year Biopsyproven diagnosis classical Hodgkin Lymphoma ( regardless HRS cell CD20 expression ) per World Health Organization classification criteria24 ; lymphocyte predominant histology exclude Untreated relapse classical Hodgkin Lymphoma ( exception steroid ) follow : HL relapse &gt; 3 month completion firstline chemotherapy combine modality therapy , yet treat salvage chemotherapy , Stage III HL relapse &gt; 3 month firstline chemotherapy , relapse radiation therapy deliver curative intent , yet treat salvage chemotherapy Radiographically measurable disease ( &gt; 1 focus lymphoma measure &gt; 1.5 cm ) Baseline laboratory : ANC &gt; 1000/uL platelet &gt; 75,000/uL , unless due bone marrow involvement lymphoma , Serum creatinine &lt; 2.0 mg/dL , Total bilirubin &lt; 2.0 mg/dL ( exclude Gilbert 's syndrome ) , unless due lymphoma ECOG performance status 0 , 1 2 . Active concurrent malignancy exception superficial nonmelanoma skin cancer cervical carcinoma situ . Primary induction failure , defined failure achieve CR firstline chemotherapy chemoradiation , disease progression firstline chemotherapy chemoradiation , progression biopsyproven disease persistence within 8 week firstline therapy completion Prior brentuximab vedotin rituximab lymphoma Grade &gt; 2 peripheral neuropathy HIV infection , active hepatitis B infection , active hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cHL</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>relapse Lymphoma</keyword>
	<keyword>SGN-35</keyword>
	<keyword>Brentuximab Vedotin</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
</DOC>